{"product_id":"global-clinical-oncology-next-generation-sequencing-market-size-study-forecast-by-technology-whole-genome-sequencing-whole-exome-sequencing-targeted-sequencing-resequencing-by-workflow-ngs-pre-sequencing-ngs-sequencing-ngs-data-analysis-by-a","title":"Global Clinical Oncology Next Generation Sequencing Market Size study \u0026 Forecast, by Technology (Whole Genome Sequencing, Whole Exome Sequencing, Targeted Sequencing \u0026 Resequencing) by Workflow (NGS Pre-Sequencing, NGS Sequencing, NGS Data Analysis), by A","description":"\u003cp\u003eGlobal Clinical Oncology Next Generation Sequencing Market Size study \u0026amp; Forecast, by Technology (Whole Genome Sequencing, Whole Exome Sequencing, Targeted Sequencing \u0026amp; Resequencing) by Workflow (NGS Pre-Sequencing, NGS Sequencing, NGS Data Analysis), by Application (Screening, Companion Diagnostics, Others), by End Use (Hospitals, Clinics, Laboratories) and Regional Analysis, 2023-2030\u003cbr\u003e\nGlobal Clinical Oncology Next Generation Sequencing Market is valued at approximately USD 370.0 million in 2022 and is anticipated to grow with a healthy growth rate of more than 15.70% over the forecast period 2023-2030. Clinical Oncology Next Generation Sequencing (NGS) refers to the application of advanced genomic sequencing technologies in the field of oncology, specifically for diagnosing and managing cancer. NGS is a high-throughput sequencing technique that enables the simultaneous analysis of multiple genes or genomic regions, providing comprehensive genetic information about a tumor. The Clinical Oncology Next Generation Sequencing market is expanding because of factors such as rising prevelance of cancer disorders, rising investment in research \u0026amp; development activities to invent solutions and growing healthcare expenditure triggering development of effective PM diagnostic \u0026amp; therapeutic procedure for cancer.\u003c\/p\u003e\n\n\u003cp\u003eThe increasing prevalence of cancer has spurred a rapid expansion of cancer research initiatives worldwide. NGS technology has become a cornerstone in cancer genomics research, facilitating large-scale genomic studies and collaborative efforts to unravel the complex genetic landscape of various cancer types. These research efforts contribute to the development of novel therapies, identification of new targets, and improved understanding of cancer biology. according to estimates from the International Agency for Research on Cancer (IARC), in year 2021 there were around 1.9 million new cancer cases across the world, and it is projected to increase at 27.5 million new cases by year 2040, worldwide. Moreover, key market players in the market are developing new platforms for the clinical uses of NGS in precision oncology resulting in market growth. For instance, a major company in the industry, In August 2022, Thermo Fisher Scientific launched NGS Analysis and Test Software CE-IVD (IVDD) in order to make precision oncology biomarker testing more widely available. Healthcare professionals can swiftly assess the outcomes of genomic tests thanks to this software. The software evaluates the variation data in light of pertinent data, such as supported recommendations, treatments, clinical studies, and peer-reviewed literature. Such developments in NGS clinical applications may increase consumer demand. In addition, technological advancements in next-generation sequencing (NGS) and growing adoption of companion diagnostics and personalized medicine is creating a lucrative opportunity in the market. However, the lack of computational efficiency for data management stifles market growth throughout the forecast period of 2023-2030.\u003c\/p\u003e\n\n\u003cp\u003eThe key regions considered for the Global Clinical Oncology Next Generation Sequencing Market study includes Asia Pacific, North America, Europe, Latin America, and Middle East \u0026amp; Africa. North America dominated the market in 2022 owing to the dominance of key market players, rising research and development for precision oncology, rising investment in development of product, and rising government support to the healthcare industry. Asia Pacific is projected to have significant growth in the market space owing to factors such as rising prevelance of cancer, rising healthcare expenditure and rising government investment in oncology drug development activities.\u003c\/p\u003e\n\n\u003cp\u003eMajor market player included in this report are:\u003cbr\u003e\nIllumina, Inc.\u003cbr\u003e\nThermo Fisher Scientific Inc.\u003cbr\u003e\nF. Hoffmann-La Roche Ltd\u003cbr\u003e\nAgilent Technologies, Inc.\u003cbr\u003e\nMyriad Genetics, Inc.\u003cbr\u003e\nBeijing Genomics Institute (BGI)\u003cbr\u003e\nPerkin Elmer, Inc.\u003cbr\u003e\nOxford Nanopore Technologies\u003cbr\u003e\nParadigm Diagnostics, Inc.\u003cbr\u003e\nPerkinElmer, Inc.\u003c\/p\u003e\n\n\u003cp\u003eRecent Developments in the Market:\u003cbr\u003e\nIn February 2023, F. Hoffmann-La Roche Ltd. and Janssen Biotech Inc. (Janssen) expanded their collaboration in order to create companion diagnostics for targeted treatments and to include a wide spectrum of companion diagnostics, including tissue- and blood-based biomarkers, digital pathology, and sequencing pathology.\u003cbr\u003e\nIn June 2023, Illumina Inc., a producer of DNA sequencing and array-based technologies, developed the artificial intelligence system PrimateAI-3D, which had previously unheard-of accuracy in foretelling disease-causing genetic defects in individuals.\u003c\/p\u003e\n\n\u003cp\u003eGlobal Clinical Oncology Next Generation Sequencing Market Report Scope:\u003cbr\u003e\nHistorical Data – 2020 - 2021\u003cbr\u003e\nBase Year for Estimation – 2022\u003cbr\u003e\nForecast period - 2023-2030\u003cbr\u003e\nReport Coverage - Revenue forecast, Company Ranking, Competitive Landscape, Growth factors, and Trends\u003cbr\u003e\nSegments Covered - Technology, Workflow, Type, End-use, Region\u003cbr\u003e\nRegional Scope - North America; Europe; Asia Pacific; Latin America; Middle East \u0026amp; Africa\u003c\/p\u003e\n\n\u003cp\u003eThe objective of the study is to define market sizes of different segments \u0026amp; countries in recent years and to forecast the values to the coming years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within countries involved in the study.\u003c\/p\u003e\n\n\u003cp\u003eThe report also caters detailed information about the crucial aspects such as driving factors \u0026amp; challenges which will define the future growth of the market. Additionally, it also incorporates potential opportunities in micro markets for stakeholders to invest along with the detailed analysis of competitive landscape and Technology offerings of key players.\u003c\/p\u003e\n\n\u003cp\u003eThe detailed segments and sub-segment of the market are explained below:\u003c\/p\u003e\n\n\u003cp\u003eBy Technology:\u003cbr\u003e\nWhole Genome Sequencing\u003cbr\u003e\nWhole Exome Sequencing\u003cbr\u003e\nTargeted Sequencing \u0026amp; Resequencing\u003c\/p\u003e\n\n\u003cp\u003eBy Workflow:\u003cbr\u003e\nNGS Pre-Sequencing\u003cbr\u003e\nNGS Sequencing\u003cbr\u003e\nNGS Data Analysis\u003cbr\u003e\nBy Application:\u003cbr\u003e\nScreening\u003cbr\u003e\nCompanion Diagnostics\u003cbr\u003e\nOthers\u003cbr\u003e\nBy End-use:\u003cbr\u003e\nHospitals\u003cbr\u003e\nClinics\u003cbr\u003e\nLaboratories\u003c\/p\u003e\n\n\u003cp\u003eBy Region:\u003c\/p\u003e\n\n\u003cp\u003eNorth America\u003cbr\u003e\nU.S.\u003cbr\u003e\nCanada\u003c\/p\u003e\n\n\u003cp\u003eEurope\u003cbr\u003e\nUK\u003cbr\u003e\nGermany\u003cbr\u003e\nFrance\u003cbr\u003e\nSpain\u003cbr\u003e\nItaly\u003cbr\u003e\nROE\u003c\/p\u003e\n\n\u003cp\u003eAsia Pacific\u003cbr\u003e\nChina\u003cbr\u003e\nIndia\u003cbr\u003e\nJapan\u003cbr\u003e\nAustralia\u003cbr\u003e\nSouth Korea\u003cbr\u003e\nRoAPAC\u003c\/p\u003e\n\n\u003cp\u003eLatin America\u003cbr\u003e\nBrazil\u003cbr\u003e\nMexico\u003c\/p\u003e\n\n\u003cp\u003eMiddle East \u0026amp; Africa\u003cbr\u003e\nSaudi Arabia\u003cbr\u003e\nSouth Africa\u003cbr\u003e\nRest of Middle East \u0026amp; Africa\u003c\/p\u003e\n\n\u003cp\u003eCompanies Mentioned\u003cbr\u003e\nIllumina, Inc.\u003cbr\u003e\nThermo Fisher Scientific Inc.\u003cbr\u003e\nF. Hoffmann-La Roche Ltd\u003cbr\u003e\nAgilent Technologies, Inc.\u003cbr\u003e\nMyriad Genetics, Inc.\u003cbr\u003e\nBeijing Genomics Institute (BGI)\u003cbr\u003e\nPerkin Elmer, Inc.\u003cbr\u003e\nOxford Nanopore Technologies\u003cbr\u003e\nParadigm Diagnostics, Inc.\u003cbr\u003e\nPerkinElmer, Inc.\u003c\/p\u003e\n\n\u003cp\u003ePlease note:The single user license is non-downloadable and non-printable. Global Site license allows these actions.\u003c\/p\u003e","brand":"Life Science","offers":[{"title":"October, 2023 \/ 200 Pages \/ MCW16232755","offer_id":47648439435570,"sku":null,"price":5940.0,"currency_code":"USD","in_stock":true}],"url":"https:\/\/www.hardmanwell.com\/products\/global-clinical-oncology-next-generation-sequencing-market-size-study-forecast-by-technology-whole-genome-sequencing-whole-exome-sequencing-targeted-sequencing-resequencing-by-workflow-ngs-pre-sequencing-ngs-sequencing-ngs-data-analysis-by-a","provider":"HARDMAN AND WELL MANAGEMENT CONSULTANCIES L.L.C","version":"1.0","type":"link"}